Specifically, examining the role of key molecular mutations, such as KRAS, NRAS, and BRAF, in TCC will provide deeper insights into the disease’s behavior and potential targeted therapeutic strategies. This evidence concerns the gene BRAF and tarsal-carpal coalition syndrome.